Investing Profile

Andrew Schiff

VC
Photo of Andrew Schiff, Managing Partner at Aisling Capital

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
Aisling Capital Managing Partner
14
$280M
CompanyStageDateRound SizeTotal Raised
Forge Biologics
Series CSep 2022$90M
$250M
Co-investors: Chris Garabedian (Perceptive Advisors), Molly McCartin (Drive Capital)
Dren Bio
Series BJun 2022$65M
$130M
Co-investors: Chandra Leo (Hbm Partners), Rajeev Dadoo (SR One), Sakae Asanuma (Taiho Ventures)
Plant Culture Systems
Pre SeedApr 2021$500K
$500K
Co-investors: Marcy Simon
Monte Rosa Therapeutics
Series BSep 2020$96M
$220M
Co-investors: Ali Behbahani (New Enterprise Associates (NEA)), Markus Warmuth (Versant Ventures), Alexander Mayweg (Versant Ventures), Chandra Leo (Hbm Partners)
Zavante Therapeutics
Series AMar 2016$45M
$45M
Co-investors: Patrick Heron (Frazier Healthcare Partners)
Agile Therapeutics
Post Ipo EquityFeb 2015$20M
Series CJul 2012$40M
$110M
Co-investors: Karen Hong (Novo Ventures), Stacey Seltzer (Aisling Capital)
Miramar Labs
Series DOct 2014$26M
$46M
Co-investors: Hank Plain (Morgenthaler Ventures)
Zeltiq Aesthetics
Series DJun 2010$25M
$50M
Co-investors: Bryan Roberts (Venrock)